RNA interference for treating haematological malignancies

Expert Opinion on Biological Therapy

Volumn 5, Issue 12, 2005, Pages 1585-1592

  Hexner, Elizabeth O ^b   Gewirtz, Alan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

Haematological malignancies; RNA interference; siRNA

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; IMATINIB; IMMUNOLIPOSOME; LIPOSOME; MICRORNA; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; MEDICAL RESEARCH; NONHUMAN; REVIEW; RNA INTERFERENCE; RNA TRANSLATION;

ANIMALS; GENE TARGETING; GENE THERAPY; HEMATOLOGIC NEOPLASMS; HUMANS; RNA INTERFERENCE; RNA, DOUBLE-STRANDED;

EID: 28844486728     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.12.1585     Document Type: Review

References (61)

1. COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348(13):1201-1214.
2. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
3. FAGARD M, BOUTET S, MOREL JB, BELLINI C, VAUCHERET H: AGO1, QDE-2, and RDE-1 are related proteins required for post-transcriptional gene silencing in plants, quelling in fungi, and RNA interference in animals. Proc. Natl. Acad. Sci. USA (2000) 97(21):11650-11654.
4. LECELLIER CH, DUNOYER P, ARAR K et al.: A cellular microRNA mediates antiviral defense in human cells. Science (2005) 308(5721):557-560.
5. TABARA H, SARKISSIAN M, KELLY WG et al.: The rde-1 gene, RNA interference, and transposon silencing in C. elegans. Cell (1999) 99(2):123-132.
6. NOVINA CD, SHARP PA: The RNAi revolution. Nature (2004) 430(6996):161-164.
7. LIM LP, LAU NC, WEINSTEIN EG et al.: The micro RNAs of Caenorhabditis elegans. Genes Dev. (2003) 17(8):991-1008.
8. GIRALDEZ AJ, CINALLI RM, GLASNER ME et al.: MicroRNAs regulate brain morphogenesis in Zebrafish. Science (2005) 308(5723):833-838.
9. CHEN CZ, LI L, LODISH HF, BARTEL DP: MicroRNAs modulate hematopoietic lineage differentiation. Science (2004) 303(5654):83-86.
10. LAGOS-QUINTANA M, RAUHUT R, YALCIN A, MEYER J, LENDECKEL W, TUSCHL T: Identification of tissue-specific microRNAs from mouse. Curr. Biol. (2002) 12(9):735-739.
11. GAUWERKY CE, HUEBNER K, ISOBE M, NOWELL PC, CROCE CM: Activation of MYC in a masked t(8;17) translocation results in an aggressive B-cell leukemia. Proc. Natl. Acad. Sci. USA (1989) 86(22):8867-8871.
12. LEE Y, AHN C, HAN J et al.: The nuclear RNase III Drosha initiates microRNA processing. Nature (2003) 425(6956):415-419.
13. YANG D, LU H, ERICKSON JW: Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos. Curr. Biol. (2000) 10(19):1191-1200.
14. ELBASHIR SM, MARTINEZ J, PATKANIOWSKA A, LENDECKEL W, TUSCHL T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. (2001) 20(23):6877-6888.
15. ZAMORE PD, TUSCHL T, SHARP PA, BARTEL DP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 101(1):25-33.
16. LIU J, CARMELL MA, RIVAS FV et al.: Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 305(5689):1437-1441.
17. SONG JJ, SMITH SK, HANNON GJ, JOSHUA-TOR L: Crystal structure of Argonaute and its implications for RISC slicer activity. Science (2004) 305(5689):1434-1437.
18. RAND TA, GINALSKI K, GRISHIN NV, WANG X: Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl. Acad. Sci. USA (2004) 101(40):14385-14389.
19. ALEXOPOULOU L, HOLT AC, MEDZHITOV R, FLAVELL RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 413(6857):732-738.
20. JUDGE AD, SOOD V, SHAW JR, FANG D, MCCLINTOCK K, MACLACHLAN I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. (2005) 23(4):457-462.
21. HORNUNG V, GUENTHNER-BILLER M, BOURQUIN C et al.: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. (2005) 11(3):263-270.
22. SIOLAS D, LERNER C, BURCHARD J et al.: Synthetic shRNAs as potent RNAi triggers. Nat. Biotechnol. (2005) 23(2):227-231.
23. KIM DH, BEHLKE MA, ROSE SD, CHANG MS, CHOI S, ROSSI JJ: Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. (2005) 23(2):222-226.
24. JOHN B, ENRIGHT AJ, ARAVIN A, TUSCHL T, SANDER C, MARKS DS: Human microRNA targets. PLoS Biol. (2004) 2(11):e363.
25. LIPPMAN Z, MARTIENSSEN R: The role of RNA interference in heterochromatic silencing. Nature (2004) 431(7006):364-370.
26. OPALINSKA JB, GEWIRTZ AM: Therapeutic potential of antisense nucleic acid molecules. Sci. STKE (2003) 2003(206):pe47.
27. OPALINSKA JB, GEWIRTZ AM: Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. (2002) 1(7):503-514.
28. DAMM-WELK C, FUCHS U, WOSSMANN W, BORKHARDT A: Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference. Semin. Cancer Biol. (2003) 13(4):283-292.
29. WENG AP, FERRANDO AA, LEE W et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306(5694):269-271.
30. PUROW BW, HAQUE RM, NOEL MW et al.: Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. (2005) 65(6):2353-2363.
31. CHI KN, GLEAVE ME, KLASA R et al.: A Phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. (2001) 7(12):3920-3927.
32. JANSEN B, WACHECK V, HEERE-RESS E et al.: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet (2000) 356(9243):1728-1733.
33. WATERS JS, WEBB A, CUNNINGHAM D et al.: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. (2000) 18(9):1812-1823.
34. WEBB A, CUNNINGHAM D, COTTER F et al.: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349(9059):1137-1141.
35. GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 293(5531):876-880.
36. REYNOLDS A LEAKE D, BOESE Q, SCARINGE S, MARSHALL WS, KHVOROVA A: Rational siRNA design for RNA interference. Nat. Biotechnol. (2004) 22(3):326-330.
37. KHVOROVA A, REYNOLDS A JAYASENA SD: Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 115(2):209-216.
38. SCHWARZ DS, HUTVAGNER G, DU T, XU Z, ARONIN N, ZAMORE PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 115(2):199-208.
39. TOMARI Y, MATRANGA C, HALEY B, MARTINEZ N, ZAMORE PD: A protein sensor for siRNA asymmetry. Science (2004) 306(5700):1377-1380.
40. CHIU YL, RANA TM: siRNA function in RNAi: a chemical modification analysis. RNA (2003) 9(9):1034-1048.
41. CHIEN PY, WANG J, CARBONARO D et al.: Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. (2005) 12(3):321-328.
42. LANDEN CN JR, CHAVEZ-REYES A, BUCANA C et al.: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. (2005) 65(15):6910-6918.
43. ZHANG Y, ZHANG YF, BRYANT J, CHARLES A, BOADO RJ, PARDRIDGE WM: Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. (2004) 10(11):3667-3677.
44. SOUTSCHEK J, AKINC A, BRAMLAGE B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 432(7014):173-178.
45. HACHEM A, GARTENHAUS RB: Oncogenes as molecular targets in lymphoma. Blood (2005) 106(6):1911-1923.
46. SONNICHSEN B, KOSKI LB, WALSH A et al.: Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Nature (2005) 434(7032):462-469.
47. ZHENG L, LIU J, BATALOV S et al.: An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA (2004) 101(1):135-140.
48. BERNS K, HIJMANS EM, MULLENDERS J et al.: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 428(6981):431-437.
49. LADETTO M, CORRADINI P, VALLET S et al.: High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood (2002) 100(5):1559-1565.
50. JACOBSEN E, FREEDMAN A: B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncol. (2004) 5(12):711-717.
51. HECKMAN CA, WHEELER MA, BOXER LM: Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene (2003) 22(39):7891-7899.
52. PTASZNIK A, NAKATA Y, KALOTA A, EMERSON SG, GEWIRTZ AM: Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. (2004) 10(11):1187-1189.
53. WEISBERG E, BOULTON C, KELLY LM et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 1(5):433-443.
54. CLARK JJ, COOLS J, CURLEY DP et al.: Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood (2004) 104(9):2867-2872.
55. WALTERS DK, STOFFREGEN EP, HEINRICH MC, DEININGER MW, DRUKER BJ: RNAi-induced downregulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood (2005) 105(7):2952-2954.
56. WOHLBOLD L, VAN DER KUIP H, MIETHING C et al.: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood (2003) 102(6):2236-2239.
57. GODFREY A, ANDERSON J, PAPANASTASIOU A, TAKEUCHI Y, BOSHOFF C: Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood (2005) 105(6):2510-2518.
58. SHEN J, SAMUL R, SILVA RL et al.: Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. (2005) (In Press).
59. ROBBINS MA, ROSSI JJ: Sensing the danger in RNA. Nat. Med. (2005) 11(3):250-251.
60. SHANKAR P, MANJUNATH N, LIEBERMAN J: The prospect of silencing disease using RNA interference. JAMA (2005) 293(11):1367-1373.
61. STEVENSON M: Therapeutic potential of RNA interference. N. Engl. J. Med. (2004) 351(17):1772-1777.